Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) (PLUTO)
PLUTO: A Prospective Phase II Study of Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy
Sponsor: Jinling Hospital, China
Terminated
Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for subjects' endpoints before and after the change.
Other terminated trials from Jinling Hospital, China
A PHASE2 clinical study on Renal Cell Carcinoma (RCC), this trial is terminated or withdrawn. The trial is conducted by Jinling Hospital, China and has accumulated 8 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Nov 2025 — Mar 2026 [monthly]
Recruiting PHASE2
-
Mar 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE2
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jinling Hospital, China
For direct contact, visit the study record on ClinicalTrials.gov .